A cutting-edge diagnostic tool developed by the University of Melbourne to diagnose hair loss and monitor treatment responses. Validated through clinical trials, this technology offers potential for FDA validation as an exploratory endpoint in male and female pattern baldness studies.
The University of Melbourne presents a novel diagnostic tool designed to accurately diagnose hair loss and monitor the efficacy of treatments, particularly focused on androgenetic alopecia (Aga). This advanced technology provides an opportunity to enhance treatment outcomes by closely tracking patient responses, thereby optimizing therapeutic approaches.
Key features:
This diagnostic tool is at Technology Readiness Level 5, indicating that it has been validated in a relevant environment. The technology is poised for further validation through upcoming phase 3 clinical trials, with potential for FDA recognition as an exploratory endpoint.
The University of Melbourne is a comprehensive institution spanning STEM, health and clinical practice, business and law, and the creative and social disciplines. Co‑located hospital and research precincts, together with an inner‑city innovation ecosystem, place companies, startups, and researchers in shared labs, prototyping spaces, and studios. Engineering and technology programs connect with advanced manufacturing facilities, while structured industry projects and placements link partners with talent and translational problem‑solving. Work is supported by competitive funding from the Australian Research Council and the National Health and Medical Research Council, with additional backing from state programs and industry partners; a dedicated technology transfer office manages IP, licensing, and startup formation.